{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T10:32:58Z","timestamp":1794393178984,"version":"4.9.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T00:00:00Z","timestamp":1555286400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1208\/s12249-019-1376-1","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T18:05:04Z","timestamp":1555351504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities"],"prefix":"10.1208","volume":"20","author":[{"given":"Naseem Ahmad","family":"Charoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areeg Anwer","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailesh Kumar","family":"Buha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyaur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,15]]},"reference":[{"key":"1376_CR1","unstructured":"FDA (2019) FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan. Accessed 21 Jan 2019. \n                    https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm613916.htm\n                    \n                  ."},{"key":"1376_CR2","unstructured":"EMA (2018) EU authorities take further action in ongoing review of sartans: Zheijiang Huahai placed under increased supervision; Aurobindo Pharma stopped from supplying irbesartan to the EU. Accessed 21 Jan 2019. \n                    https:\/\/www.ema.europa.eu\/en\/news\/eu-authorities-take-further-action-ongoing-review-sartans-zheijiang-huahai-placed-under-increased#_ftn1"},{"key":"1376_CR3","unstructured":"Shanley A. After Valsartan Recalls, Regulators grapple with nitrosamine contamination in APIs. Pharma Tech 2018. Accessed 21 Jan 2019. \n                    http:\/\/www.pharmtech.com\/after-valsartan-recalls-regulators-grapple-nitrosamine-contamination-apis"},{"key":"1376_CR4","unstructured":"EMA (2018b) Press release on 13th September. Update on review of valsartan medicines: risk from NDMA remains low, a related substance NDEA also being investigated. Accessed 21 Jan 2019. \n                    https:\/\/www.ema.europa.eu\/en\/news\/update-review-valsartan-medicines-risk-ndma-remains-low-related-substance-ndea-also-being"},{"key":"1376_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3851","volume":"362","author":"A Pottegard","year":"2018","unstructured":"Pottegard A, Kristensen K, Ernst MT, Johansen NB, Quartorolo P, Hallas J. Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study. Br Med J. 2018;362:k3851.","journal-title":"Br Med J"},{"key":"1376_CR6","unstructured":"IARC (1978) Some N-nitroso Compounds: IARC monographs on the evaluation of carcinogenic risk of chemicals to humans. International Agency for Research on Cancer, Lyon, France."},{"key":"1376_CR7","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/oxfordjournals.aje.a117029","volume":"139","author":"CA Gonz\u00e1lez","year":"1994","unstructured":"Gonz\u00e1lez CA, Riboli E, Badosa J, Batiste E, Cardona T, Pita S, et al. Nutritional factors and gastric cancer in Spain. Am J Epidemiol. 1994;139:466\u201373.","journal-title":"Am J Epidemiol"},{"key":"1376_CR8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/00008469-199512000-00005","volume":"4","author":"C Vecchia La","year":"1995","unstructured":"La Vecchia C, D\u2019Avanzo B, Airoldi L, Braga C, Decarli A. Nitrosamine intake and gastric cancer. Eur J Cancer Prev. 1995;4:469\u201374.","journal-title":"Eur J Cancer Prev"},{"key":"1376_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/BF01719947","volume":"11","author":"D Pobel","year":"1995","unstructured":"Pobel D, Riboli E, Corn\u00e9e J, H\u00e9mon B, Guyader M. Nitrosamine, nitrate and nitrite in relation to gastric cancer: a case\u2013control study in Marseille, France. Eur J Epidemiol. 1995;11:67\u201373.","journal-title":"Eur J Epidemiol"},{"key":"1376_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/00001648-199207000-00004","volume":"3","author":"MT Goodman","year":"1992","unstructured":"Goodman MT, Hankin JH, Wilkens LR, Kolonel LN. High fat foods and the risk of lung cancer. Epidemiology. 1992;3:288\u201399.","journal-title":"Epidemiology"},{"key":"1376_CR11","unstructured":"De Stefani E, Deneo-Pellegrini H, Carzoglio JC, Ronco A, Mendilaharsu M. Dietary nitrosodimethylamine and the risk of lung cancer: a case\u2013control study from Uruguay. Cancer Epidemiol Biomarkers Prev. 1196(5):679\u201382."},{"key":"1376_CR12","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/(SICI)1097-0215(19990315)80:6<852::AID-IJC9>3.0.CO;2-S","volume":"80","author":"P Knekt","year":"1999","unstructured":"Knekt P, J\u00e4rvinen R, Dich J, Hakulinen T. Risk of colorectal and other gastro-intestinal cancers after exposure to nitrate, nitrite and N-nitroso compounds: a follow-up study. Int J Cancer. 1999;80:852\u20136.","journal-title":"Int J Cancer"},{"key":"1376_CR13","first-page":"241","volume":"2","author":"MC Archer","year":"1989","unstructured":"Archer MC. Mechanisms of action of N-nitroso compounds. Cancer Surv. 1989;2:241\u201350.","journal-title":"Cancer Surv"},{"issue":"7","key":"1376_CR14","first-page":"1281","volume":"57","author":"D Nakae","year":"1997","unstructured":"Nakae D, Kobayashi Y, Akai H. Involvement of 8-hydroxyguanine formation in the initiation of rat liver carcinogenesis by low dose levels of N-nitrosodiethylamine. Cancer Res. 1997;57(7):1281\u20137.","journal-title":"Cancer Res"},{"issue":"7","key":"1376_CR15","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1093\/carcin\/15.7.1451","volume":"15","author":"YP Dragan","year":"1994","unstructured":"Dragan YP, Hully JR, Nakamura J, Mass MJ, Swenberg JA, Pitot HC. Biochemical events during initiation of rat hepatocarcinogenesis. Carcinogenesis. 1994;15(7):1451\u20138.","journal-title":"Carcinogenesis"},{"key":"1376_CR16","unstructured":"EPA Integrated Risk Information System (IRIS). \u201cN-nitrosodimethylamine; CASRN 1993; 62\u201375-9.\u201d \n                    https:\/\/cfpub.epa.gov\/ncea\/iris\/iris_documents\/documents\/subst\/0045_summary.pdf\n                    \n                   Accessed 21 Jan 2019."},{"key":"1376_CR17","unstructured":"WHO (2008). N-nitrosodimethylamine in drinking-water. Background document for preparation of WHO Guidelines for drinking-water quality. Geneva, World Health Organization (WHO\/HSE\/AMR\/08.03\/8). Accessed 21 Jan 2019. \n                    https:\/\/www.who.int\/water_sanitation_health\/dwq\/chemicals\/ndmasummary_2ndadd.pdf"},{"key":"1376_CR18","unstructured":"FDA (1996) FDA compliance policy guides manual: sec. 510.600 dimethylnitrosamine in malt beverages. US Food and Drug Administration, Washington, DC."},{"key":"1376_CR19","unstructured":"FDA (1995) FDA compliance policy guides manual: sec. 578.500 dimethylnitrosamine in barley malt. US Food and Drug Administration, Washington, DC."},{"key":"1376_CR20","unstructured":"ICH (2006) IMPURITIES IN NEW DRUG SUBSTANCES Q3A(R2). Accessed 21 Jan 2019. \n                    https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q3A_R2\/Step4\/Q3A_R2__Guideline.pdf"},{"issue":"13","key":"1376_CR21","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1016\/j.watres.2013.04.050","volume":"47","author":"SW Krasner","year":"2013","unstructured":"Krasner SW, Mitch WA, McCurry DL, Hanigan D, Westerhoff P. Formation, precursors, control, and occurrence of nitrosamines in drinking water: a review. Water Res. 2013;47(13):4433\u201350.","journal-title":"Water Res"},{"issue":"5","key":"1376_CR22","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1021\/es035025n","volume":"38","author":"WA Mitch","year":"2004","unstructured":"Mitch WA, Sedlak DL. Characterization and fate of N-nitrosodimethylamine precursors in municipal wastewater treatment plants. Environ Sci Technol. 2004;38(5):1445\u201354.","journal-title":"Environ Sci Technol"},{"key":"1376_CR23","unstructured":"FDA (2008) Genotoxic and carcinogenic impurities in drug substances and products: recommended approaches. Draft guidance. Accessed 21 Jan 2019. \n                    http:\/\/www.triphasepharmasolutions.com\/Resources\/Guidance%20for%20Industry%20Genotoxic%20Agents.pdf"},{"key":"1376_CR24","unstructured":"EMA (2006) Guideline on the limits of genotoxic impurities. Accessed on Jan 21, 2019. \n                    https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-limits-genotoxic-impurities_en.pdf"},{"key":"1376_CR25","unstructured":"FDA (2019) Combined N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) impurity assay by GC\/MS-headspace. Available at: \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM623198.pdf\n                    \n                   (Accessed 6th March 2019)."},{"key":"1376_CR26","unstructured":"EDQM (2018) OMCLs release three methods for determination of NDMA in sartans. Available at: \n                    \n                      https:\/\/www.edqm.eu\/en\/news\/omcls-release-three-methods-determination-ndma-sartans\n                    \n                    \n                  \n                           . (Accessed 6\n                           th March 2019)."},{"key":"1376_CR27","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1021\/op900338g","volume":"14","author":"AR Looker","year":"2010","unstructured":"Looker AR, Ryan MP, Neubert-Langille BJ, Naji R. Risk assessment of potentially genotoxic impurities within the framework of quality by design. Org Process Res Dev. 2010;14:1032\u20136.","journal-title":"Org Process Res Dev"},{"key":"1376_CR28","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1021\/op900242x","volume":"14","author":"Z Cimarosti","year":"2010","unstructured":"Cimarosti Z, Bravo F, Stonestreet P, Tinazzi F, Vecchi O, Camurri G. Application of quality by design principles to support development of a control strategy for the control of genotoxic impurities in the manufacturing process of a drug substance. Org Process Res Dev. 2010;14:993\u20138.","journal-title":"Org Process Res Dev"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-019-1376-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-019-1376-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-019-1376-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T23:04:11Z","timestamp":1586819051000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-019-1376-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,15]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["1376"],"URL":"https:\/\/doi.org\/10.1208\/s12249-019-1376-1","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,15]]},"assertion":[{"value":"4 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"166"}}